Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda
19 oct. 2023 09h16 HE
|
Sabin Vaccine Institute
WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers...
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
17 oct. 2023 07h00 HE
|
AC Immune SA
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
Study Published in Science Translational Medicine Shows Exbaq’s Experimental Vaccine Protects Against Many of the Most Dangerous Antibiotic Resistant Superbugs Causing Hospital Acquired Infections
05 oct. 2023 09h00 HE
|
Exbaq LLC
Vaccine Stimulates the Body’s Macrophages, Engulfing and Killing Gram Positive/Negative Bacteria, and FungiVaccine provides protection against infections within 24hours and protection lasts for up to...
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
26 sept. 2023 16h01 HE
|
HilleVax, Inc.
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Paediatric Vaccine Market Projections: Surging at a Striking 13.1% CAGR, Anticipating US$ 184,706.7 Million Valuation by 2033 | Future Market Insights, Inc.
25 sept. 2023 13h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del:, Sept. 25, 2023 (GLOBE NEWSWIRE) -- In 2023, the paediatric vaccine market is expected to be worth US$ 54,130.1 million. The market is expected to grow at a remarkable 13.1% CAGR to a...
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
25 sept. 2023 07h00 HE
|
HilleVax, Inc.
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Vaccinex, Inc. Announces Reverse Stock Split
22 sept. 2023 16h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Europe Continuous Bioprocessing Market to be Worth $206.1 Million by 2030- Exclusive Report by Meticulous Research®
20 sept. 2023 09h00 HE
|
Meticulous Market Research Pvt. Ltd.
Redding, California, Sept. 20, 2023 (GLOBE NEWSWIRE) -- According to a new market research report, “Europe Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges,...
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
20 sept. 2023 08h26 HE
|
Evaxion Biotech
Partnership based on a highly protective vaccine candidate identified by Evaxion’s EDEN™ platformThe collaboration will access mRNA technology from the WHO and Medicines Patent Pool’s mRNA Vaccine...
HilleVax Announces Pricing of Public Offering of Common Stock
19 sept. 2023 20h05 HE
|
HilleVax, Inc.
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...